Edition:
India

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

51.55USD
26 Aug 2016
Change (% chg)

$0.35 (+0.68%)
Prev Close
$51.20
Open
$51.20
Day's High
$51.97
Day's Low
$51.18
Volume
1,112,484
Avg. Vol
1,224,251
52-wk High
$66.55
52-wk Low
$48.01

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000... (more)

Overall

Beta: 0.78
Market Cap(Mil.): $52,758.72
Shares Outstanding(Mil.): 1,014.36
Dividend: 0.34
Yield (%): 2.64

Financials

  TEVA.N Industry Sector
P/E (TTM): 34.42 36.93 36.63
EPS (TTM): 1.50 -- --
ROI: 4.12 14.69 14.12
ROE: 5.06 15.48 15.04

BRIEF-Moody's says Teva's loss of two copaxone patents is credit negative

* Moody's on Teva Pharmaceutical - there is no change to Teva Pharmaceutical Industries LTD Baa2 senior unsecured rating or stable outlook Source text for Eikon:

26 Aug 2016

UPDATE 2-Mylan wins round in fight with Teva over multiple sclerosis drug

WASHINGTON, Aug 24 Pharmaceutical company Mylan NV has won a round in its fight with Teva Pharmaceutical Industries Ltd at the U.S. Patent and Trademark Office, which said on Wednesday that two patents for the multiple sclerosis drug Copaxone sold by Teva were, after a review process, considered unpatentable.

25 Aug 2016

UPDATE 1-Mylan wins round in fight with Teva over multiple sclerosis drug

WASHINGTON, Aug 24 Pharmaceutical company Mylan NV has won a round in its fight with Teva Pharmaceutical Industries Ltd at the U.S. Patent and Trademark Office, which said on Wednesday that two patents for the multiple sclerosis drug Copaxone sold by Teva were, after a review process, considered unpatentable.

25 Aug 2016

BRIEF-Teva confirms PTAB's decisions on two patents in IPR challenge to Copaxone

* Teva confirms PTAB's decisions on two patents in IPR challenge to Copaxone 40 mg

25 Aug 2016

BRIEF-Mylan invalidates two of Teva's Copaxone patents

* Mylan invalidates two of Teva's Copaxone 40 mg/ml patents via U.S. Patent and Trademark Office's Inter Partes Review proceeding

25 Aug 2016

BRIEF- European Commission has granted Teva Pharmaceutical marketing authorization for cinqaero in 28 countries

* European Commission has granted marketing authorization for Cinqaero (reslizumab) in 28 countries of European Union in addition to Norway

18 Aug 2016

Mesoblast cell treatment shows promise in rheumatoid arthritis - study

Mesoblast Ltd on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial.

09 Aug 2016

Mesoblast cell treatment shows promise in rheumatoid arthritis : study

Mesoblast Ltd on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial.

09 Aug 2016

Mesoblast cell treatment shows promise in rheumatoid arthritis -study

Aug 8 Mesoblast Ltd on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial.

09 Aug 2016

BRIEF-Allergan Equico reports 9.9 pct stake in Teva Pharmaceutical

* Reports a stake of 9.9 pct in Teva Pharmaceutical Industries Ltd as of July 27, 2016 - SEC filing Source text: (http://bit.ly/2aHghJE) Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

09 Aug 2016

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF77.40 +0.10
Biogen Inc (BIIB.OQ) $308.17 +1.32

Earnings vs. Estimates